$2.68T
Total marketcap
$46.23B
Total volume
BTC 49.83%     ETH 17.10%
Dominance

Haemonetics Corporation HAZ.F Stock

80.5 EUR {{ price }} -0.617284% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
4.14B EUR
LOW - HIGH [24H]
80.5 - 80.5 EUR
VOLUME [24H]
10 EUR
{{ volume }}
P/E Ratio
38.15
Earnings per share
2.11 EUR

Haemonetics Corporation Price Chart

Haemonetics Corporation HAZ.F Financial and Trading Overview

Haemonetics Corporation stock price 80.5 EUR
Previous Close 75 EUR
Open 75 EUR
Bid 75 EUR x 12100
Ask 77.5 EUR x 11600
Day's Range 75 - 75 EUR
52 Week Range 56 - 85.5 EUR
Volume 5 EUR
Avg. Volume 0 EUR
Market Cap 3.86B EUR
Beta (5Y Monthly) 0.429225
PE Ratio (TTM) 37.878788
EPS (TTM) 2.11 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 79.25 EUR

HAZ.F Valuation Measures

Enterprise Value 4.44B EUR
Trailing P/E 37.878788
Forward P/E 25
PEG Ratio (5 yr expected) 2.39
Price/Sales (ttm) 3.3046694
Price/Book (mrq) 4.625632
Enterprise Value/Revenue 3.797
Enterprise Value/EBITDA 17.031

Trading Information

Haemonetics Corporation Stock Price History

Beta (5Y Monthly) 0.429225
52-Week Change 37.50%
S&P500 52-Week Change 20.43%
52 Week High 85.5 EUR
52 Week Low 56 EUR
50-Day Moving Average 76.44 EUR
200-Day Moving Average 76.02 EUR

HAZ.F Share Statistics

Avg. Volume (3 month) 0 EUR
Avg. Daily Volume (10-Days) 0 EUR
Shares Outstanding 50.54M
Float 50.21M
Short Ratio N/A
% Held by Insiders 0.67%
% Held by Institutions 100.95%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends April 1, 2023
Most Recent Quarter (mrq) April 1, 2023
Next Fiscal Year End April 1, 2024

Profitability

Profit Margin 9.87%
Operating Margin (ttm) 14.30%
Gross Margin 53.29%
EBITDA Margin 22.29%

Management Effectiveness

Return on Assets (ttm) 5.50%
Return on Equity (ttm) 14.72%

Income Statement

Revenue (ttm) 1.17B EUR
Revenue Per Share (ttm) 23.01 EUR
Quarterly Revenue Growth (yoy) 14.89%
Gross Profit (ttm) N/A
EBITDA 260.51M EUR
Net Income Avi to Common (ttm) 115.4M EUR
Diluted EPS (ttm) 1.98
Quarterly Earnings Growth (yoy) 201.59%

Balance Sheet

Total Cash (mrq) 285.58M EUR
Total Cash Per Share (mrq) 5.65 EUR
Total Debt (mrq) 830.76M EUR
Total Debt/Equity (mrq) 101.56 EUR
Current Ratio (mrq) 3.057
Book Value Per Share (mrq) 16.214

Cash Flow Statement

Operating Cash Flow (ttm) 273.06M EUR
Levered Free Cash Flow (ttm) 133.19M EUR

Profile of Haemonetics Corporation

Country Germany
State MA
City Boston
Address 125 Summer Street
ZIP 02110
Phone 781 848 7100
Website https://www.haemonetics.com
Industry Medical Instruments & Supplies
Sector(s) Healthcare
Full Time Employees 3034

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Q&A For Haemonetics Corporation Stock

What is a current HAZ.F stock price?

Haemonetics Corporation HAZ.F stock price today per share is 80.5 EUR.

How to purchase Haemonetics Corporation stock?

You can buy HAZ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Haemonetics Corporation?

The stock symbol or ticker of Haemonetics Corporation is HAZ.F.

Which industry does the Haemonetics Corporation company belong to?

The Haemonetics Corporation industry is Medical Instruments & Supplies.

How many shares does Haemonetics Corporation have in circulation?

The max supply of Haemonetics Corporation shares is 51.41M.

What is Haemonetics Corporation Price to Earnings Ratio (PE Ratio)?

Haemonetics Corporation PE Ratio is 38.15166000 now.

What was Haemonetics Corporation earnings per share over the trailing 12 months (TTM)?

Haemonetics Corporation EPS is 2.11 EUR over the trailing 12 months.

Which sector does the Haemonetics Corporation company belong to?

The Haemonetics Corporation sector is Healthcare.